LOGIN  |  REGISTER
Terns Pharmaceuticals
Viking Therapeutics

Illumina To Webcast Upcoming Investor Conference

May 14, 2025 | Last Trade: US$101.80 2.51 2.53

SAN DIEGO, May 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:

  • 41st Annual Bernstein Strategic Decisions Conference on May 28, 2025
    Fireside chat at 11:30am Pacific Time (2:30pm Eastern Time)

The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com. A replay will be posted on Illumina's website after the event and will be available for at least 30 days following.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter)FacebookLinkedInInstagramTikTok, and YouTube.

Investors:
Brian Blanchett
+1.858.291.6421 
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media:
Christine Douglass
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Recursion

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page